美股A股
StockGist
Back
10-K2026-03-31· glm-5

MIRA · MIRA Pharmaceuticals, Inc.

0001493152-26-014001

SEC filing

Summary

MIRA Pharmaceuticals reported a net loss of $10.4 million for fiscal year 2025, reflecting the capital-intensive nature of advancing its clinical-stage neuroscience pipeline. Operating cash usage of $4.7 million underscores the company's focus on development activities, with current resources expected to fund operations into at least the first quarter of 2027.

Key takeaways

Full analysis

Clinical-Stage Operating Profile

MIRA Pharmaceuticals, a clinical-stage company advancing two neuroscience programs targeting neurologic and neuropsychiatric disorders, reported a net loss of $10.4 million for the fiscal year ended December 31, 2025, translating to a diluted loss per share of $1.35. These results reflect the inherent financial dynamics of a development-stage pharmaceutical company that has not yet commercialized its product candidates. Operating expenses have historically centered on patent prosecution and initial investments in pre-clinical research and development activities.

Research and Development Dynamics

The company experienced a decrease in research and development expenses during 2025, attributable to reduced development costs for MIRA-55. This reduction highlights the variable nature of R&D spending as programs transition between development phases. However, management anticipates a reversal of this trend, expecting R&D expenses to increase as both Ketamir-2 and MIRA-55 advance into and through clinical trials. This pipeline progression will require significant investment in clinical trials, regulatory support, and contract manufacturing.

Administrative and Overhead Trends

Offsetting the reduction in R&D spending, general and administrative expenses increased during 2025. This increase relates primarily to growth in stock-based compensation and payroll-related expenses, reflecting the administrative infrastructure required to support a public company and advancing clinical programs. The resulting net loss position underscores the challenge of balancing operational investment with the capital constraints typical of the clinical-stage biopharmaceutical sector.

Cash Flow and Liquidity Position

Net cash used in operating activities totaled $4.7 million for the fiscal year, a reflection of the ongoing funding requirements for development operations. Management currently expects that existing cash and cash equivalents will be sufficient to fund operations, development plans, and capital expenditures into at least the first quarter of 2027. This runway provides a critical buffer as the company works to advance its pipeline candidates through value-inflection clinical milestones.

Going Concern and Capital Requirements

Despite the extended runway, substantial doubt about the company's ability to continue as a going concern remains a central consideration for investors. Management has explicitly stated that if the company is unable to raise additional capital or secure additional lending in the near future, it may need to curtail operations. This dependency on external financing introduces execution risk, particularly given the capital-intensive nature of clinical development. The company's ability to successfully advance Ketamir-2 and MIRA-55 will depend on both clinical success and continued access to capital markets.